Sequenom

Limmi Strengthens Board with Addition of Healthcare Industry Executive and Technology Veteran

Retrieved on: 
Wednesday, December 6, 2023
Sale, Viasat, Multimedia, Education minister, Viasat (American company), Growth, AI, Management, Limmy, Sequenom

Rob Lozuk, a healthcare executive and CEO of Syantra, a leader and innovator in liquid biopsy cancer and disease detection, along with Todd Lewis, Vice President at Viasat, a global satellite technology company, have been selected to join Limmi's leadership team.

Key Points: 
  • Rob Lozuk, a healthcare executive and CEO of Syantra, a leader and innovator in liquid biopsy cancer and disease detection, along with Todd Lewis, Vice President at Viasat, a global satellite technology company, have been selected to join Limmi's leadership team.
  • Mr. Lozuk has spent the past 23 years successfully scaling and transacting commercially disruptive technologies across the healthcare arena.
  • Mr. Lewis has spent his career focused on innovative and emerging technologies, including executive positions at Wildblue Communications and OnCommand Corporation.
  • "As Limmi enters a phase of accelerated growth, the insights and experience that Rob and Todd bring to our board are invaluable," said Trevor Vieweg, Chairman of Limmi.

MEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor

Retrieved on: 
Tuesday, June 13, 2023
Oncology, Health, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Employment, Arthur Andersen, Information technology, Central Washington University, Cancer, Woman, Certified Public Accountant, Mergers and acquisitions, Patient, Sequenom, Knowledge, MEI, Treasurer, Compensated emancipation, Pharmaceutical industry, Security (finance), Science, Finance, Accounting

File joined the Company on June 12, 2023 as Executive Vice President, Finance and will be appointed Chief Financial Officer upon Mr. Drazba’s departure.

Key Points: 
  • File joined the Company on June 12, 2023 as Executive Vice President, Finance and will be appointed Chief Financial Officer upon Mr. Drazba’s departure.
  • It has been a privilege working with him, and he will be missed by the MEI team,” stated David M. Urso, president and chief executive officer of MEI Pharma.
  • File.
  • File was the Chief Financial Officer of Evofem Biosciences, Inc., a women's health company that developed and commercialized Phexxi®, a nonhormonal contraceptive for women.

JUNO DIAGNOSTICS STRENGTHENS THE ORGANIZATION WITH APPOINTMENT OF GINA GRAYUM TO COMMERCIAL LEADERSHIP TEAM

Retrieved on: 
Tuesday, October 18, 2022
SAN, LinkedIn, Woman, Women's health, Sequenom, Phlebotomy, Patient, Collection, GenePeeks, Company, Marketing, Health, Genetic testing, NIPS, Pharmaceutical industry, Management, Invitae

SAN DIEGO, Oct. 18, 2022 /PRNewswire/ -- Juno Diagnostics (JunoDx), a company focused on bringing vital health information to patients by improving access, affordability and transparency, today announced the addition of Gina Grayum to its commercial leadership team.

Key Points: 
  • SAN DIEGO, Oct. 18, 2022 /PRNewswire/ -- Juno Diagnostics (JunoDx), a company focused on bringing vital health information to patients by improving access, affordability and transparency, today announced the addition of Gina Grayum to its commercial leadership team.
  • Ms. Grayum brings more than a decade of diagnostics sales and management experience to JunoDx, most recently as U.S.
  • "We are excited to welcome someone of Gina's caliber to the JunoDx leadership team.
  • Juno Diagnostics is a category defining health company bringing vital prenatal health information to patients by combining access, affordability and transparency.

Ansa Bio Appoints Lorna Neilson, Ph.D. as Chief Business Officer

Retrieved on: 
Tuesday, September 6, 2022
Biotechnology, Genetics, Health, Molecular biology, Enzyme, University, CEO, Technology, Synthetic biology, Applied Biosystems, Research, Agriculture, California State University, Sequenom, Corporate development, LinkedIn, DNA, Method, University of California, San Diego, Thermo Fisher Scientific, Medicine, Leadership, Doctor of Philosophy, Twitter, Biotechnology, University of Southern California, Molecular genetics, Marketing, Bachelor of Arts, Management, Fine chemical, Biology, Ansa, Invitrogen

Ansa Biotechnologies , a pioneer of next-generation DNA synthesis, today announced the appointment of Lorna Neilson, Ph.D., as Chief Business Officer.

Key Points: 
  • Ansa Biotechnologies , a pioneer of next-generation DNA synthesis, today announced the appointment of Lorna Neilson, Ph.D., as Chief Business Officer.
  • She brings to Ansa more than 20 years of life sciences leadership experience, from business and corporate development to marketing and new product development.
  • Lorna will be responsible for shaping Ansas commercial business strategy and leading the expansion of its commercial operations and team.
  • Lorna has extensive business development experience with several globally recognized life sciences companies and has a very strong track record of commercializing new technologies and driving business growth, said Daniel Lin-Arlow, CEO & Co-Founder.

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications

Retrieved on: 
Tuesday, May 31, 2022
Senior, Cancer, MBA, Risk, History, Perivascular epithelioid cell tumour, Pharmacology, Private Securities Litigation Reform Act, Doctor of Philosophy, Anderson School of Management, Corporate Affairs, Patient, NASDAQ, Corporate communication, Therapy, Stanford Graduate School of Business, TSC2, TSC1, COVID-19, Failure, Adult, Novartis, FDA, Sequenom, AADI, MTOR, Daiichi Sankyo, Forward-looking statement, Strategy, University, Safety, Management, Journalism, LinkedIn, Twitter, Acquisition, GLOBE, Business, Ambit Biosciences, Aadi, Pharmaceutical industry

LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced the appointment of Marcy Graham to the new position of Senior Vice President, Investor Relations (IR) and Corporate Communications.

Key Points: 
  • LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced the appointment of Marcy Graham to the new position of Senior Vice President, Investor Relations (IR) and Corporate Communications.
  • We are delighted to welcome Marcy to the team, as she brings extensive experience to the senior role of investor relations and corporate communications and a strong history of relationship building with investors and other key external audiences, said Neil Desai, PhD, Founder, President and Chief Executive Officer of Aadi Bioscience.
  • Ms. Graham brings more than 20 years of biotech and pharma-specific investor relations and corporate communications experience, leading these functional areas at companies in all stages of development.
  • She joins Aadi after most recently serving as the Vice President of Corporate Affairs at Poseida Therapeutics and previously as Vice President IR and Corporate Communications at Mirati Therapeutics.

Juno Diagnostics™ to Exhibit at the American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting

Retrieved on: 
Wednesday, May 4, 2022
ACMG, Prenatal care, Booth, Population, American College, Phlebotomy, ACOG, NIPS, Physician, Patient, ACSM, Genetic counseling, DNA, Sequenom, Science, Solution, SAN, American College of Obstetricians and Gynecologists, Medical imaging, Gynaecology

SAN DIEGO, May 4, 2022 /PRNewswire-PRWeb/ -- Juno Diagnostics™, Inc. (JunoDx™), a women's health company focused on improving equitable access to prenatal care led by industry experts, will be exhibiting at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting (ACSM) in San Diego, May 6-8, 2022, at Booth #1023.

Key Points: 
  • Annual Clinical and Scientific Meeting to take place May 6-8, 2022
    SAN DIEGO, May 4, 2022 /PRNewswire-PRWeb/ -- Juno Diagnostics, Inc. (JunoDx), a women's health company focused on improving equitable access to prenatal care led by industry experts, will be exhibiting at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting (ACSM) in San Diego, May 6-8, 2022, at Booth #1023.
  • "Our cell-free DNA-based non-invasive prenatal screening solutions are designed to significantly improve access to high-quality genetic results.
  • We offer NIPS with the right support and without the high cost, long lead times, and inconvenient phlebotomy requirements of traditional NIPS."
  • Juno Diagnostics is a company developing innovative solutions to improve access to vital health information.

Small Pharma Strengthens Board With Appointment of Paul Maier as Independent Director

Retrieved on: 
Thursday, November 18, 2021
Committee, Financial compensation, Harvard Graduate School of Arts and Sciences, Indian stock exchange, Corporate governance, Â, Brain, Apricus Biosciences, Company, DMT, Audit committee, Ligand Pharmaceuticals, MBA, MDD, ISCO, Leadership, Imperial College London, Business, Program, Biological Dynamics of Forest Fragments Project, Pharma, Plant, CDN, OTCBB, GLOBE, Sequenom, Board, N, Depression, Option, Mammal, NASDAQ, Growth, Initial public offering, IP, Security (finance), Pharmaceutical industry

LONDON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the Company or Small Pharma), a neuropharmaceutical company focused on psychedelic-assisted therapies, announces that Mr. Paul Maier has been appointed as a non-executive independent director of the board of directors of the Company (the Board).

Key Points: 
  • LONDON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the Company or Small Pharma), a neuropharmaceutical company focused on psychedelic-assisted therapies, announces that Mr. Paul Maier has been appointed as a non-executive independent director of the board of directors of the Company (the Board).
  • Mr. Maier joins Small Pharma with over 30 years experience in senior executive roles across the biopharmaceutical and biotech industry.
  • Lyne Fortin, Chair of the Board of Small Pharma, said: We are delighted to welcome someone of Pauls calibre to the Board of Small Pharma.
  • Mr. Maier added: It is an honor to join the Small Pharma Board at this exciting juncture for the Company.

U.S. Non-Invasive Prenatal Testing Market Research and Outlook Report 2021-2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 1, 2021
Health, General Health, Midwifery, Branches of biology, Prenatal testing, Biology, Articles, Prenatal development, Invasive species, Sequenom, NIPT

Key Questions Answered in this Report:

Key Points: 
  • Key Questions Answered in this Report:
    What is the current scenario of the United States non-invasive prenatal testing market?
  • What is the total market size and forecast (until 2028) for the United States non-invasive prenatal testing market?
  • What is the regulatory framework in the United States non-invasive prenatal testing market?
  • What are the major deals and agreement happenings in the United States non-invasive prenatal testing market?

Trillium Therapeutics Appoints Catherine Mackey, Ph.D., to Its Board of Directors

Retrieved on: 
Wednesday, June 30, 2021
Microarrays, Sequenom

CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Trillium or the Company) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointment of pharmaceutical industry leader Catherine Mackey, Ph.D., to its Board of Directors, effective immediately.

Key Points: 
  • CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Trillium or the Company) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointment of pharmaceutical industry leader Catherine Mackey, Ph.D., to its Board of Directors, effective immediately.
  • We are excited to welcome Dr. Mackey to our board of directors, said Paolo Pucci, Lead Director of Trillium.
  • Dr. Mackey has more than 30 years of operating experience in the pharmaceutical and biotechnology sectors.
  • Dr. Mackey previously served as a director of Poseida Therapeutics, GW Pharmaceuticals, YM Biosciences, Evolve Biosystems, Sequenom Inc., and Viventia Bio.

Non-Invasive Prenatal Testing Market Size To Reach $6.5 Billion By 2028, Based On Increasing Occurrence of Chromosomal Abnormalities & Rising Usage of Product in Novel Functions | Million Insights

Retrieved on: 
Tuesday, June 8, 2021
Clinical medicine, Medicine, Prenatal sex discernment, NIPT, Prenatal testing, Amniocentesis, Chorionic villus sampling, Sequenom, Nuchal scan

The exercise of the invasive method of prenatal testing, for example amniocentesis and chorionic villus sampling, can initiate problems, like miscarriage.

Key Points: 
  • The exercise of the invasive method of prenatal testing, for example amniocentesis and chorionic villus sampling, can initiate problems, like miscarriage.
  • Please click here to get the sample pdf and find more details on "Non-Invasive Prenatal Testing (NIPT) Market"Report 2028.
  • Due to the existence of constructive compensation strategy in this sector, non invasive prenatal testing for standard & high risk pregnancy, dominated the market.
  • Browse 150 page research report with TOC on "Global Non-Invasive Prenatal Testing Market" at: https://www.millioninsights.com/industry-reports/global-non-invasive-pre...
    Million Insights segmented the global non-invasive prenatal testing market based on End Use, Product, Technology, Method, Gestation Period, Risk Type, and Region:
    NIPT Gestation Period Outlook (Revenue, USD Million, 2017 - 2028)